KPMW135 / Biohaven - LARVOL DELTA

Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting (GlobeNewswire) - "Data showed that KPMW135 increased anti-tumor activity by at least a factor of 10 by adding T cell mediated cytotoxicity to rituximab’s existing mechanism of action. These data are being presented at the 62nd Annual American Society of Hematology (ASH) Meeting, being held Dec 5-8, 2020 in a virtual format."

Preclinical • Hematological Malignancies • Oncology

Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE) at The 62nd Annual Society of Hematology (ASH) Meeting (GlobeNewswire) - "Kleo Pharmaceuticals, Inc...announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan®) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62^nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020."

Preclinical • Hematological Malignancies • Oncology